Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00516386 · ClinicalTrials.gov registry record · Phase 1
Safety Profile of Insulin Like Growth Factor-1 (IGF-I) Administration in Adolescents
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT00516386: Completed Phase 1 study, sponsored by Massachusetts General Hospital.
NCT00516386 is a Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00516386, a Phase 1 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study was to determine whether giving insulin like growth factor-I (IGF-I) to adolescent low weight girls is safe and whether this increases levels of bone formation markers.
Interventions
- DRUG RhIGF-1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2007-03 |
| Est. Completion | 2008-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00516386
The ClinicalTrials.gov registry entry for NCT00516386 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RhIGF-1 is the first listed.
NCT00516386 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00516386 about?
NCT00516386 is a clinical study titled "Safety Profile of Insulin Like Growth Factor-1 (IGF-I) Administration in Adolescents". The purpose of this study was to determine whether giving insulin like growth factor-I (IGF-I) to adolescent low weight girls is safe and whether this increases levels of bone formation markers.
What is the current status of trial NCT00516386?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2007-03. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00516386?
The interventions under investigation include: RhIGF-1 (DRUG).
Who is sponsoring clinical trial NCT00516386?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.